To amend the Internal Revenue Code of 1986 to provide for a credit against tax for expenses for translational research regarding neurodegenerative diseases and psychiatric conditions.

To amend the Internal Revenue Code of 1986 to provide for a credit against tax for expenses for translational research regarding neurodegenerative diseases and psychiatric conditions. 1. Short title This Act may be cited as the Mental Health Research Accelerator Act of 2022 2. Expenses for certain translational research (a) In general Subpart D of part IV of subchapter A of chapter 1 45U. Expenses for certain translational research (a) Allowance of credit For purposes of section 38, the translational research credit determined under this section for any taxable year shall be an amount equal to 25 percent of the amounts paid or incurred by such taxpayer during such taxable year which are necessary for translational research regarding neurodegenerative diseases and psychiatric conditions. (b) Limitation (1) Taxpayer limitation The credit allowed under this section to a taxpayer for a taxable year beginning in any calendar year shall not exceed the portion of the limitation amount allocated to the taxpayer under this subsection reduced by the amount of credit allowed to the taxpayer under this section for all prior taxable years. (2) Aggregate national limitation (A) In general There is a translational research credit limitation for each calendar year as follows: (i) $1,000,000,000 for 2022. (ii) $2,000,000,000 for each of years 2023 through 2027. (iii) $1,000,000,000 for 2028. (B) Allocation of limitation As expeditiously as possible, the Secretary shall allocate among applicants selected by the Secretary the limitation under paragraph (2) for all years. (C) Regulations The Secretary shall prescribe regulations as may be necessary to carry out the purposes of this section, including establishing the application process and the criteria for allocation under the preceding sentence. Such regulations shall include the following: (i) Amounts shall be allocated based on scientific merit. (ii) Projects should include all phases of the research continuum. (iii) An emphasis on new therapeutics and devices targeted at central nervous system disorders and in the neurological and psychiatric fields. (iv) Standards for repurposing existing drugs and devices for new purposes. (v) Standards for public-private partnerships with priority given to collaborative efforts and sharing of intellectual property. (c) Transfer of credit (1) In general If, with respect to a credit under subsection (a) for any taxable year— (A) a tax-exempt entity would be the taxpayer (but for this paragraph), and (B) such entity elects the application of this paragraph for such taxable year with respect to all (or any portion specified in such election) of such credit, the eligible project partner specified in such election, and not the tax-exempt entity, shall be treated as the taxpayer for purposes of this title with respect to such credit (or such portion thereof). (2) Definitions For purposes of this subsection— (A) Tax-exempt entity The term tax-exempt entity (i) a Federal, State, or local government entity, or any political subdivision, agency, or instrumentality thereof, and (ii) an organization described in section 501(c)(3) and exempt from tax under section 501(a). (B) Eligible project partner The term eligible project partner (i) is identified in the application for allocation of credit under this section as a project partner, and (ii) participates in, or provides funding for, the research with respect to which limitation was allocated by the Secretary under subsection (b). (3) Special rules (A) In general In the case of a credit under subsection (a) which is determined at the partnership level— (i) for purposes of paragraph (1)(A), a tax-exempt entity shall be treated as the taxpayer with respect to such entity’s distributive share of such credit, and (ii) the term eligible project partner (B) Taxable year in which credit taken into account In the case of any credit (or portion thereof) with respect to which an election is made under paragraph (1), such credit shall be taken into account in the first taxable year of the eligible project partner ending with, or after, the tax-exempt entity’s taxable year with respect to which the credit was determined. (d) Coordination with credit for increasing research expenditures (1) In general Except as provided in paragraph (2), any expenses taken into account under this section shall not be taken into account for purposes of determining the credit allowable under section 41 for such taxable year. (2) Expenses included in determining base period research expenses Any expenses taken into account under this section which are qualified research expenses (within the meaning of section 41(b)) shall be taken into account in determining base period research expenses for purposes of applying section 41 to subsequent taxable years. (e) Termination No credit shall be allowed under this section for any taxable year beginning after December 31, 2032. . (b) Deduction disallowed Section 280C of such Code is amended by adding at the end the following new subsection: (i) Credit for certain translational research No deduction shall be allowed for that portion of the expenses taken into account under section 45U otherwise allowable as a deduction for the taxable year which is equal to the amount of the credit determined for such taxable year under such section. . (c) Credit made part of general business credit Subsection (b) of section 38 plus , plus (34) the credit determined under section 45U. . (d) Clerical amendment The table of sections for subpart D of part IV of subchapter A of chapter 1 of such Code is amended by adding at the end the following new item: Sec. 45U. Expenses for certain translational research. (e) Effective date The amendments made by this subsection shall take effect on the date of the enactment of this Act.

Summary: Mental Health Research Accelerator Act of 2022 This bill allows a tax credit through 2031 for 25% of expenses for translational research regarding neurodegenerative diseases and psychiatric conditions. The credit amount is subject to limitations, including an aggregate national limitation of $1 billion in 2022, $2 billion in 2023-2027, and $1 billion in 2028.